BioMarin appeases an activist

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with news of an averted activist challenge, biotech on late-night TV, and the latest deal in oncology’s hottest space.

BioMarin appeases an activist

Alexander Hardy, the new CEO of BioMarin Pharmaceutical, had an unenviable introduction to the job. Weeks before his first day, Elliott Management, a famed and formidable activist investor, disclosed a sizable stake in BioMarin, suggesting trouble ahead for a management team that had yet to get started.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In